2019-10-22 09:50:261970-01-01 00:00:00

FPH Posted Record High Earnings

Fisher & Paykel Healthcare (FPH) released its full year financial results for 2019 today, reported a 10% increase in net profit after tax to NZ$209 million. The company’s revenue surpassed the $1 billion milestones, up 9% compared to the previous fiscal year.

Operating revenue was $1070.4 million. The company’s gross margin improved by 56 basis points to 66.9%, compared to the long term target of 65%. Operating expenses accumulated to $428.2 million. The 11% increase in expense was driven by higher patent litigation expenses, continued investment in research and development (R&D) to support global sales growth and the global ERP implementation.

FPH offers medical devices in two business sectors; hospital and homecare. The products are for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea (OSA). The record high gains were mainly attributed by strong sales in hospital equipment, followed by homecare products and others. Hospital contributed 60% to total operating revenue. The company reported a 12% increase in hospital sales to $642.3 million, driven by strong sales growth in Optiflow; accounted for 62% of its product sales. For homecare products, the operating revenue grew by 6%, reporting $421.4 million. Distributed and other products had $6.7 million in revenue.

In the financial year for 2020, the company is expecting to generate $1.15 billion of operating revenue and around $240 million of net profit after tax. NFP’s new production factory in Tijuana, Mexico was completed. The facility is expected to operate in the coming fiscal year. Further investment had occurred in Auckland, New Zealand. The construction work of a fourth building in the area is expected to be completed and operational in 2020. More than $150 million was exhausted in capital expenditure in the 2019 financial year. Over the long term, the company plans to keep R&D annual cost growth to be in line with revenue growth.

In the days leading up to the financial announcement, the strong gains were anticipated by ASX investors as FPH’s share price was trading at a record high at $15.81 last week. The company’s stock also traded at a record high on the NZX at $16.67. On the same day as the announcement, FPH also notified dividend distribution. The imputed final dividend is expected to be 13.5 NZ cents per share. The total annual dividend of 23.25 NZ cents a share is up 9% on the year. Given the strong performance over the last five years, the board has suspended the dividend reinvestment plan. However, since the announcements, the ASX listed share price has dropped more than 4% at $15.12 in the morning.

FPH’s operation in foreign countries

FPH is primarily an exporting company. The products are sold in over 120 countries worldwide, mainly in regions including North America, Europe, Asia-Pacific and others. In terms of total sales, almost 50% of total sales was comprised of revenue from North America. European sales contributed 29% of its total revenue and 20% coming from the Asia Pacific. North America generated $501.5 million in operating revenue. This was a 9% increase from the last fiscal year. Sales in Europe grew by nearly 6% to $314.6 million. For revenue in the Asia Pacific, $208.1 million were made, a growth of 15% from the previous year. The rest of the regions contributed $46.2 million in revenue.

With the majority of its sales from foreign countries, FPH is exposed to movements in foreign exchange rates. The operating revenue was generated in a wide range of currencies mainly in US dollars (50%), Euros (19%), Australian dollars (6%) and Japanese yen (5%). Only 1% of the sales were generated domestically. While the company implemented strategies to hedge against currency risk, currency headwinds contributed a loss of $1.9 million to operating profit. However, new hedging in USD and EUR is expected to realise benefits in future periods.

Healthcare industry

Resmed, one of the dominant players in the health care industry, has been in patent infringement disputes with FPH in a number of countries, costing each of the companies millions of dollars. The disputes dated all the way back to 2016 and the net intellectual property litigation expenses amounted to $23.4 million for FPH in the fiscal year 2019. In February 2019, Resmed and FPH reached an agreement to drop all outstanding disputes with no payment by either party. The settlement will significantly reduce patent litigation costs in the coming year.

The demand for quality healthcare continues to rise. Healthcare providers are constantly seeking solutions that provide a better patient experience. In terms of context, ageing population and technology advancement in the industry will be the key to secure market capitalisation. For FPH, its focus on innovative products will be crucial in the business’s growth. Furthermore, the company continues to identify opportunities to expand. As the population increases, the growing demand in China and India can offer significant potential for FPH.

By Jack Lee

Click here for a 7 days access to our Lotus Blue Portal.

KOSEC does not take into account the investment objectives, financial situation and advisory needs of any particular person, nor does the information provided constitute investment advice. Under no circumstances should investments be based solely on the information provided. KOSEC is intended to provide general information only. Please be aware that investing involves the risk of capital loss. This message is confidential and may be privileged. It is intended only for the use of the addressee named above. If you are not the intended recipient, any unauthorised dissemination, distribution or copying is illegal. We do not guarantee the security or completeness of information hereby transmitted and are not liable in either respect or in respect of any delay. Nothing in this message is intended as an offer or solicitation for the purchase or sale of any financial instrument. Any market prices or data, unless specifically verified and identified as such, are not warranted as to completeness or accuracy. Kodari Securities Pty Ltd (KOSEC) is a Corporate Authorised Representative (No. 399 556) of Longhou Capital Markets (AFSL No. 292464) which is regulated by the Australian Securities and Investment Commission (ASIC). KOSEC wishes to disclose that KOSEC and its staff may hold stock they recommend in their own portfolios and that any decision to purchase recommended stock should be done so after the purchaser has made their own inquires as to the suitability to their own requirements. Click here to view our FSG.

KOSEC Terms & Conditions

Kodari Securities Pty Ltd (CAR 399556) trading as KOSEC is regulated by the Australian Securities and Investment Commission (ASIC). KOSEC is a financial services company and any information provided by its platforms, portals, reports and documents is protected by copyright. Any unauthorised production of this information is prohibited.
KOSEC reserves the right to change or remove any information provided on our website, reports or any documents including these terms and conditions at any time without notice. The change or modification to the terms and conditions will be effective immediately upon posting an updated version on our website, necessary platforms and documents. It is recommended that you review the information provided on our website, including these terms and conditions frequently for any changes.

Disclaimer
KOSEC provides general advice only. The information provided is of a general nature only and does not take into account your individual objectives, financial situation or needs. It should not be used, relied upon, or treated as a substitute for specific professional advice. KOSEC recommends that you obtain your own independent professional advice before making any decision in relation to your particular requirements or circumstances. Please make sure you read our Financial Services Guide (FSG).

KOSEC does not guarantee any returns. Past performance of any product discussed is not indicative of future performance. (We urge that caution should be exercised in assessing past performance. All financial products are subject to market forces and unpredictable events that may adversely affect their future performance). Investing in the stock market can incur huge losses. Please also be aware that fees will incur on every transaction regardless of the performance of your investments or returns generated. Employees and or associates of KOSEC may hold one or more of the stocks, securities or investments reviewed by the company.

Your use of information from our website, reports, documents and from talking to our representatives/associates is at your risk. Under no circumstance should the investment be based solely on KOSEC information and general advice. You should seek professional financial planning advice.
KOSEC aims to maintain the accuracy of the data and information provided on this website, by using information prepared from a wide variety of sources, which KOSEC to the best of its knowledge and belief, considers accurate and does not make any representations or warranties of any kind, expressed or implied, about the completeness, accuracy, reliability, suitability or availability of the information provided.

We may at times refer to third parties, which the details of these third parties have been provided solely for you to obtain further information about other relevant products and entities in the market. KOSEC has no control over the information third parties have, or the products or services offered, and therefore make no representations regarding the accuracy or suitability of such information, products or services. You are advised to make your own enquiries in relation to third parties. Our inclusion of any third party content is not an endorsement of that content or the third party.

Fees
As a client you will be charged a yearly service fee and a set brokerage fee per transaction. Your service fee will automatically renew at the end of your agreed 12 month period at the same rate advertised at the time. Your credit card or bank account will be charged for a further year following which will again auto renew until you cancel your yearly service fee. You can cancel the auto renewal at any time in advance of the renewal date by contacting us. KOSEC is aware of the need to ensure the security of your credit card details and our payment systems are compliant with the Payment Card Industry (PCI) Data Security Standard.

Privacy
You consent to receiving email correspondence from KOSEC, as well as companies KOSEC has an association with. These emails will be sent by KOSEC and third party companies. You can opt out of receiving any category of emails at any time by contacting us. We may from time to time inform you of special offers, or even ask your opinion of the services we provide, but your involvement is optional. Should you request us to do so, we will archive your details.

Indemnity and Liability
You indemnify KOSEC from all claims or threatened claims, suits, demands, damages, costs as well as including legal costs incurred in dealing with any threatened claim, expenses made by any person or corporation against KOSEC and any other amounts which is caused by KOSEC providing information, execution and General Advice.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from a decision made by you on the basis of information obtained through the use of our portal, reports, documents or any General Advice given and any transaction taken place.

You hold KOSEC harmless and release it from any liability in respect of any loss, harm or damage arising from delays in executing orders for the client and acknowledges KOSEC makes no guarantees about the time taken to execute an order on behalf of the client. You acknowledge that KOSEC relies on third parties in providing technology and release KOSEC from any harm, loss or damage you may suffer as a result of the failure of such information technology.

Cookies and Links
KOSEC website, and its portal uses cookies, which lets us identify your browser while you are using the site or our portal. Cookies do not identify you personally. They simply allow us to track your usage patterns. If you prefer not to receive cookies, you can configure your browser to reject them or to notify you when they are being used. The functionality of the KOSEC website may be impacted if you restrict the use of cookies.

Fill up the form below and we will get back to you as soon as possible.

CLAIM YOUR FREE E-BOOK &
7 DAY ACCESS TO LOTUS BLUE

STOCK MARKET SUCCESS

KOSEC’s CEO, Michael Kodari’s new book, “Stock Market Success” valued at $39.95, available at Dymocks book stores with all the proceeds going to Dymocks Children’s Charities.

CLAIM YOUR FREE E-BOOK WHEN YOU LOGIN TO LOTUS BLUE INVESTMENT PORTAL

Latest TV Commercial